secwatch.observer — SEC 8-K summary
======================================

Issuer:     IN8BIO, INC. (INAB)
CIK:        0001740279
Form:       8-K
Filed at:   2024-06-03T23:59:59+00:00
Accession:  0001193125-24-152493
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IN8bio reports 92% of INB-200 patients exceed 7-month PFS in Phase 1 GBM study
------------------------------------------------------------------------------

- 92% of evaluable patients exceeded median PFS of 7 months (Stupp regimen); median follow-up 11.7 months.
- One Cohort 2 patient alive and progression-free at 34.9+ months; IDH-mutant glioma case.
- No CRS, ICANS, or dose-limiting toxicities; common AEs were Grade 1-2 related to TMZ.
- Phase 2 INB-400 now dosing newly diagnosed GBM patients with up to six infusions.
- Radiographic improvements included resolution of midline shift and 36% lesion decrease in one patient.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740279/000119312524152493/0001193125-24-152493-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740279/000119312524152493/d777605d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-152493

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer